S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Peter Clark, MA, MD, FRCP: A Payer Perspective

Jul

Today In Oncology

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Peter Clark, MA, MD, FRCP: A Payer Perspective

Metastatic Castration-Resistant Prostate Cancer Comparison of Second-Line Regimens

AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative

HER3-DXd in NSCLC Without EGFR-Activating Mutations

Survey Shows Inaccuracies in US Perceptions of Testicular Cancer

utDNA May Help to Personalize Bladder Cancer Treatment